Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04901936 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 2 of 12 sitesv4
  2. Primary completion date: Apr 2024 to Dec 2028 Study sites: 10 to 12 · Completion date: Oct 2024 to Dec 2028v3 Show 2 more changesShow less
    • Study sites: 10 to 12
    • Completion date: Oct 2024 to Dec 2028
  3. Study sites: 1 to 10 Secondary endpoints revised (9) · Study description expanded, about 28 words · Eligibility criteria expanded, about 1 wordv2 Show 3 more changesShow less
    • Secondary endpoints revised (9)
    • Study description expanded, about 28 words
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).
Trial Details
NCT Number NCT04901936
Lead Sponsor Apellis Pharmaceuticals, Inc.
Conditions Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov